References
- BAARNH1ELM, C., DAHLBACK, H. and SKANBERG, I., 1986, In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacologica et Toxologica, 59, 113–122.
- BOXENBAUM, H., 1980, Interspecies variation in liver weight, hepatic blood flow and antipyrine intrinsic clearance in extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics and Biopharmacology, 8, 165–176.
- CHIBA, M., FuTrTA, S. and Suzum, T., 1990a, Kinetic properties of the metabolism of imipramine and despramine in isolated rat hepatocytes. Biochemical Pharmacology, 39, 367–372.
- CHIBA, M., FuTrTA, S. and Suzum, T., 1990b, Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and despramine in rats. Journal of Pharmaceutical Science, 79, 281–287.
- DEDRICK, R. L., ZAHARKO, D. S. and LUTZ, R. L., 1973, Transport and binding of methotrexate in vivo. Journal of Pharmaceutical Science, 62, 882–890.
- GILLETTE, J. R., 1984, Problems in correlating in vitro and in vivo studies of drug metabolism. In L. Z. Benet G. Levy and B. L. Ferraiole (eds), Pharmacokinetics: A Modem View (New York: Plenum), pp. 235–252.
- HANANO M., SAWADA, Y., IGA, T. and SUGIYAMA, Y., 1987, The integration of in vitro data with physiological data. In D. D. Brimer and P. Speeder (eds), Topics in Pharmaceutical Science (Amsterdam: Elsevier), pp. 63–77.
- HOUSTON, J. B., 1994, Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology, 47, 1469–1479.
- JoLY, J. G., DOYON C. and PESANT Y, 1975, Cytochrome P450 measurement in rat liver homogenate and microsomes. Its use for correction of micros omal losses incurred by differential centrifugation. Drug Metabolism and Disposition, 3, 577–586.
- KAMATAKI, T., 1974, Effect of lypophilization and storage of rat liver microsomes on activity of aniline hydroxylase, contents of cytochrome b5 and cytochrome P-450 and aniline-induced P-450 difference spectrum. Journal of Pharmacology, 24, 195–203.
- LIN, J. H., HAYASHI, M., AWAZU, S. and HANANO, M., 1978, Correlation between in vitro and in vivo drug metabolism rate: Oxidation of ethoxybenzamide in rat. Journal of Pharmacokinetics and Biopharmacology, 6, 327–337.
- LE.T, J. H., SUGIYAMA, Y., AWAZU, S. and HANANO, M., 1982, Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. Journal of Pharmacokinetics and Biopharmacology, 10, 649–661.
- LOWRY, O. H., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
- MATSUI, K. and MISHEVIA, M., 1999, Absorption, distribution, metabolism and excretion of donepezil (Aricepto) after a single oral administration (in preparation).
- PANG, K. S. and CHIBA, M., 1994, Metabolism: scaling-up from in vitro to organ and whole body. In P. C. Welling and L. P. Balant (eds), Handbook of Experimental Pharmacology (New York: Springer), pp. 101–187.
- PANG, K. S. and ROWLAND, M., 1977, Hepatic clearance of drugs. III. Additional experimental evidence supporting the 'well-stirred' model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liver in situ preparation. Journal of Pharmacokinetics and Biopharmacology, 5, 681–699.
- RHO, J. P. and LIPSON, L. G., 1997, Formulary, 32, 7.
- ROBERTS, M. S. and ROWLAND, M., 1986a, A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. Journal of Pharmacokinetics and Biopharmacology, 14, 227–260.
- ROBERTS, M. S. and ROWLAND, M., 1986b, A dispersion model of hepatic elimination: 3. Application to metabolite formation and elimination kinetics. Journal of Pharmacokinetics and Biopharmacology, 14, 289–308.
- ROBINSON, P. J., BASS, L., POND, S. M., ROBERTS, M. S. and WAGNER, J. G., 1988, Clinical applicability of current pharmacokinetic models: splanchnic elimination of 5-fluorouracil in cancer patients. Journal of Pharmacokinetics and Biopharmacology, 16, 229–249.
- ROGERS, S. L., DOODY, R. S., Moxs, R. C. and FRIEDHOFF, L. T., 1998, Archives of Internal Medicine, 158, 1021.
- ROWLAND, M., BENET, L. Z. and GRAHAM, G. G., 1973, Clearance concepts in pharmacokinetics. Journal of Pharmacokinetics and Biopharmacology, 1, 123–136.
- SUGIYAMA, Y., SAWADA, Y., IGA, T. and HANANO, M., 1989, Reconstruction of in vivo metabolism from in vitro data. In R. Kato, I. LW. Estabrook and M. N. Cayen (eds), Xenobiotic Metabolism and Disposition (London: Taylor & Francis), pp. 225–235.
- WILKINSON, G. R., 1987, Clearance approaches in pharmacology. Pharmacology Reviews, 39, 1-47. WILKINSON, G. R. and SHAND, D. G., 1975, Commentary: a physiological approach to hepatic drug clearance. Clinical Pharmacology, 18, 377–390.
- YAMANISHI, Y., 1990, Basic clinical and therapeutic aspect of Alzheimer's and Parkinson's diseases, 2, 409.
- YAMAOKA, K., 1981, A pharmacokinetic analysis program (MULTI) for microcomputer. Journal of Pharmacobio-Dynamics, 4, 879–885.